By Dr. Paul Hahn | Business Insider/BBC News”The first human trial of an herbal remedy to treat dementia in people with Alzheimer’s disease has started in Switzerland.
The trial, which aims to test a new medication that may be able to slow the progression of the disease, is funded by a grant from the Swiss National Science Foundation, a foundation that aims to promote scientific research in medicine.
The drug, called amelioratrin, is being tested in Alzheimer’s patients by a Swiss group that has also partnered with a pharmaceutical company in Switzerland and in a study of people with mild cognitive impairment in the United States.
The study, funded by the Swiss-Swiss Center for Disease Prevention and Control, was designed to test whether ameliarin could reduce the progression or even halt the progression in people diagnosed with Alzheimer and have mild cognitive symptoms.
It is being conducted by researchers at the Institute of Biomedical Engineering and Technology in Lausanne, Switzerland.
Its also being conducted in the U.S., according to Dr. David Pomeranz, the director of the institute and a member of the Alzheimer’s Disease Prevention Program at the University of California, San Francisco, and a lead author of the paper.
In a statement, the institute said that the trial will involve a group of Alzheimer’s risk factors and the drug is “being tested in a small, randomised trial of 1,200 people, with an expected enrollment of 1.6 million.”
It added that its preliminary results showed ameliratrin “treats the disease in a reasonable manner, and does not induce side effects that can interfere with treatment.””
The trials will be carried out in the coming weeks, with the goal of conducting another phase of clinical trials in 2021.
“According to a news release from the Alzheimer Disease Prevention Center, the drug could be used to help people who are “slowly or dramatically progressing in the progression to Alzheimer’s.
“It said that it was also developing a second compound, which is a synthetic derivative of amelorin, that is being developed for use in Alzheimer disease treatment, but which does not affect the main ingredient of amaliratrins.”
This compound is a more potent inhibitor of amyloid beta than amelin and is not intended for use as a drug for treating Alzheimer’s,” the statement added.”
However, it may be useful for the treatment of patients with mild dementia, such as mild cognitive impairments, and who are taking other drugs or taking different medications.
“Amelioratorin is being manufactured by Swiss drugmaker Sanofi, and the researchers involved in the trial said in a statement that the compound was developed as part of a clinical trial to “study the effectiveness of an ameloid inhibitor against a specific Alzheimer’s-related protein called amyloproteins.””
In the future, we hope to test our compound in other forms and to further develop it to develop additional pharmaceutical formulations, so that it can be used as a more targeted treatment,” the researchers added.
The news release noted that ameliteratrin is “currently being tested for its ability to reverse mild cognitive deficits in people.””
This is the first human study of an Alzheimer’s drug to be conducted using an amylomiratin derivative in a clinical setting,” it said.
The researchers also noted that they are “currently recruiting participants for additional trials, and are awaiting results from these trials before deciding on further clinical trials.”
The researchers said that their clinical trials “will provide the basis for the next step in our ongoing efforts to explore the therapeutic potential of amlioratrin in Alzheimer-related disorders.”
The Swiss drug company is also working with a company in the US to conduct a trial to test the drug in people who have been diagnosed with mild mild cognitive disorders.
In addition to the Alzheimer disease prevention study, the Swiss researchers also hope to conduct clinical trials to see if ameligorin can improve the symptoms of Alzheimer.